Cytokinetics, Incorporated

NASDAQ:CYTK

54.09 (USD) • At close September 6, 2024
Bedrijfsnaam Cytokinetics, Incorporated
Symbool CYTK
Munteenheid USD
Prijs 54.09
Beurswaarde 6,364,229,400
Dividendpercentage 0%
52-weken bereik 25.98 - 110.25
Industrie Biotechnology
Sector Healthcare
CEO Mr. Robert I. Blum
Website https://www.cytokinetics.com

An error occurred while fetching data.

Over Cytokinetics, Incorporated

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is

Vergelijkbare Aandelen

Blueprint Medicines Corporation logo

Blueprint Medicines Corporation

BPMC

86.43 USD

Inari Medical, Inc. logo

Inari Medical, Inc.

NARI

45.52 USD

CureVac N.V. logo

CureVac N.V.

CVAC

2.74 USD

Ultragenyx Pharmaceutical Inc. logo

Ultragenyx Pharmaceutical Inc.

RARE

55.24 USD

Intellia Therapeutics, Inc. logo

Intellia Therapeutics, Inc.

NTLA

19.72 USD

Mirati Therapeutics, Inc. logo

Mirati Therapeutics, Inc.

MRTX

58.7 USD

Merit Medical Systems, Inc. logo

Merit Medical Systems, Inc.

MMSI

96.58 USD

Karuna Therapeutics, Inc. logo

Karuna Therapeutics, Inc.

KRTX

329.83 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)